- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of July 24
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 24, 2017.
Transcript
Hi, I’m Kelly Davio for the Center for Biosimilars, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 24.
Number 5: FDA Commissioner, Dr Scott Gottlieb, along with the acting director of the Federal Trade Commission, testified before the House Judiciary Committee on Thursday concerning antitrust issues and the FDA approval process.
Number 4: A recent report on the current pipeline of biopharmaceuticals shows 749 projects under development for diabetes and diabetes-related complications.
Number 3: The House of Representatives passed the Medicare Part B Improvement Act, but the bill could face funding issues after CMS proposed a cut to payment for home healthcare.
Number 2: The prospective adalimumab biosimilar CinnoRA was shown in a recent phase 3 trial to be noninferior to Humira.
And finally, Number 1: This week, Merck announced the US launch of its biosimilar infliximab, Renflexis, at a 35% discount to Remicade.
Read these articles and more at centerforbiosimilars.com.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 1st 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
